Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials

Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France.
Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association (Impact Factor: 7.9). 06/2008; 6(6):644-53. DOI: 10.1016/j.cgh.2008.03.014
Source: PubMed


We performed a meta-analysis of placebo-controlled trials to evaluate safety and efficacy of tumor necrosis factor (TNF) antagonists for Crohn's disease.
We searched MEDLINE, Cochrane Library, and EMBASE. The primary end points were clinical remission for luminal Crohn's disease and fistula closure at > or =2 consecutive visits. Deaths, serious infections, and malignancies were also analyzed by the methods of Peto and Der Simonian and Laird.
Fourteen luminal Crohn's disease trials enrolled 3995 patients. In overall analysis, anti-TNF therapy was effective for induction of remission at week 4 (mean difference, 11%; 95% confidence interval [CI], 6%-16%; P < .001) and maintenance of remission at weeks 20-30 in patients who responded to induction therapy and in patients randomized before induction (mean difference, 23%; 95% CI, 18%-28% and mean difference, 8%; 95% CI, 3%-12%, respectively; P < .001 for all comparisons). Ten studies evaluated anti-TNF for treatment of fistulizing Crohn's disease, involving 776 patients. In overall analysis, anti-TNF therapy was effective for fistula closure only in maintenance trials after open-label induction (mean difference, 16%; 95% CI, 8%-25%; P < .001). In 21 studies enrolling 5356 individuals, anti-TNF therapy did not increase the risk of death, malignancy, or serious infection.
Infliximab, adalimumab, and certolizumab are effective in luminal Crohn's disease. Efficacy of anti-TNF agents other than infliximab in treating fistulizing Crohn's disease requires additional investigations. A longer duration of follow-up and a larger number of patients are required to better assess the safety profile of TNF antagonists in Crohn's disease.

Download full-text


Available from: Pierre Deltenre,
1 Follower
64 Reads
  • Source
    • "Anti-TNF therapy is at present the most effective, but also the most costly therapy for IBD. The most frequently used anti-TNF therapies, infliximab and adalumimab, have a sustained response rate of between 21 and 48% [82] [83]. Because of the extremely high costs of these drugs a test that could predict their effectiveness would be highly lucrative. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory bowel disease, consisting of Crohn’s disease and ulcerative colitis, is a chronic inflammatory disease of the gut, which arises through an excessive immune response to the normal gut flora in a genetically susceptible host. The disease affects predominantly young adults and due to its chronic and relapsing nature gives rise to a high disease burden both financially, physically and psychologically. Current therapy still cannot prevent the need for surgical intervention in more than half of IBD patients. Consequently, advances in IBD therapy are of high importance. Recently, several new forms of targeted therapy have been introduced, which should improve surgery-free prognosis of IBD patients. Recent identification of genetic risk variants for IBD has led to new insights into the biological mechanisms of the disease, which will, in the future, lead to new targeted therapy. In the meantime repositioning of drugs from biologically similar diseases towards IBD might lead to new IBD therapies.
    Baillière&#x027 s Best Practice and Research in Clinical Gastroenterology 06/2014; 28(3). DOI:10.1016/j.bpg.2014.04.002 · 3.48 Impact Factor
  • Source
    • "For example , a study from the Swedish TNF-antagonist registry found that 44% of patients were still taking their initial therapy at five years, and 25% were no longer taking any TNF antagonist at all [25]. As for IBD, up to 50% of patients lose response to treatment (secondary nonresponders) and up to 30% do not respond at all (primary nonresponders) [27]. The rational for lack or loss of response is multifactorial: molecular structure of biologic drug, pharmacokinetics, pharmacodynamics, and development of anti-drug antibodies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical response in patients with rheumatoid arthritis (RA) treated with biologic agents can be influenced by their pharmacokinetics and immunogenicity. The present study evaluated the concordance between serum drug and antidrug levels as well as the clinical response in RA patients treated with biological agents who experience their first disease exacerbation while being on a stable biologic treatment. 154 RA patients treated with rituximab (RTX), infliximab (IFX), adalimumab (ADL), or etanercept (ETN) were included. DAS28, SDAI, and EULAR response were assessed at baseline and reevaluated at precise time intervals. At the time of their first sign of inadequate response, patients were tested for both serum drug level and antidrug antibodies level. At the next reevaluation, patients retreated with RTX that had detectable drug level had a better EULAR response (P = 0.038) with lower DAS28 and SDAI scores (P = 0.01 and P = 0.03). The same tendency was observed in patients treated with IFX and ETN regarding EULAR response (P = 0.002 and P = 0.023), DAS28 score (P = 0.002 and P = 0.003), and SDAI score (P = 0.001 and P = 0.026). Detectable biologic drug levels correlated with a better clinical response in patients experiencing their first RA inadequate response while being on a stable biologic treatment with RTX, IFX, and ETN.
    BioMed Research International 05/2014; 2014:702701. DOI:10.1155/2014/702701 · 2.71 Impact Factor
  • Source
    • "The introduction of monoclonal antibodies, commonly known as biologics and fusion proteins has dramatically changed the clinical management and the course of immune mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis (Pso), Crohn's disease (CD) and ulcerative colitis (UC) [1] [2] [3]. The use of anti TNFs, such as infliximab, etanercept, adalimumab, certolizumab, and golimumab, and new molecules, such as ustekinumab, an anti-IL-12/23 monoclonal antibody, represents important therapeutic options in patients refractory to conventional immunosuppressive treatments, or that need prolonged and frequent courses of steroids. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Biological agents are widely used in rheumatology, dermatology and inflammatory bowel disease. Evidence about their efficacy and safety has been strengthened for all those therapeutic indications over the last decade. Biosimilar agents are monoclonal antibodies similar to previously approved biologics. In the European Union, they have been approved for all the indications in the management of immune-mediated inflammatory diseases (IMIDs), although data only in rheumatoid arthritis and ankylosing spondylitis are currently available. Direct evidence on efficacy, safety, and immunogenicity of biosimilars is mandatory in psoriasis, psoriatic arthritis, and inflammatory bowel disease, as well as in children. Based on the current evidence in the literature, we present the joint official position of the Italian Societies of Rheumatology, Dermatology and Inflammatory Bowel Disease on the use of biosimilars in IMIDs.
    Autoimmunity reviews 03/2014; 13(7). DOI:10.1016/j.autrev.2014.02.004 · 7.93 Impact Factor
Show more